Candel Therapeutics (CADL)
Develops viral immunotherapies for solid tumors through adenovirus and HSV platforms.
Something off on this page? Send us feedback.
Develops off-the-shelf viral immunotherapies for solid tumors, led by aglatimagene in prostate cancer and lung cancer and linoserpaturev in recurrent high-grade glioma. Operates as a pre-revenue, one-segment biotech whose progress depends on clinical trials, FDA review, manufacturing readiness, and financing.
Develops off-the-shelf viral immunotherapies designed to trigger systemic anti-tumor immune responses in solid tumors. Aglatimagene besadenovec anchors the adenovirus platform, with BLA readiness in localized prostate cancer and a global pivotal AURORA trial in metastatic non-squamous NSCLC.
Linoserpaturev leads the HSV platform in recurrent high-grade glioma, while enLIGHTEN remains a preclinical HSV-based discovery platform for additional solid-tumor programs. The company reports one segment and has not generated product sales.
Execution is centered in Needham, Massachusetts, with development priorities tied to FDA review, clinical-trial readouts, launch-readiness work, manufacturing planning, and access to external capital.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 29, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: — | Target: $23 |
| Jul 13, 2026 | Stifel Nicolaus | Target | Target: — | Target: $22 |
| Oct 27, 2025 | Stephens | Target | Target: — | Target: $15 |
| Sep 3, 2025 | B of A Securities | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $201.6M · Total debt $49.5M · Total assets $208.1M · Shareholders' equity $126.1M
- Revenue
- $0
- Operating income
- −$26.7M
- Net income
- −$38.9M
No dividends on record.
| Institutions | ≈ 66.28% | 50.72M shares | |
|---|---|---|---|
| 146 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 8.85% | 6.77M shares | |
| 11 holders · as of Sep 11, 2026 | |||
| Other | ≈ 24.87% | 19.03M shares | |
| remainder | |||
76.52M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 14.36% | 10.99M | as of Jun 30, 2026 |
RTW Investments, LPInstitution | 8.39% | 6.42M | as of Jun 30, 2026 |
Paul B. Manning1Insiderdirector | 7.57% | 5.79M | filed Mar 18, 2026 |
BlackRock, Inc.Institution | 6.49% | 4.97M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.64% | 3.55M | as of Jun 30, 2026 |
- Paul B. Manning's transaction reports restate only vehicles that traded; the 2026 ownership statement (5.79M) is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 11, 2026 | Paul Peter Tak | director, officer: Chief Executive Officer | −59,379 | $10.46 |
| Sep 10, 2026 | Paul Peter Tak | director, officer: Chief Executive Officer | −220,866 | $11.50 |
| Aug 17, 2026 | Seshu Tyagarajan | officer: Chief Technology Officer | −7,000 | $12.00 |
| Jun 29, 2026 | Seshu Tyagarajan | officer: Chief Technology Officer | −7,000 | $10.02 |
| Jun 29, 2026 | Francesca Barone | officer: Chief Scientific Officer | −23,447 | $10.06 |
- Replimune Group
Direct HSV oncolytic peer with BLA-stage RP1
- CG Oncology
Late-stage oncolytic immunotherapy peer in bladder cancer
- Genelux
Oncolytic vaccinia peer with lung and ovarian programs
- Oncolytics Biotech
Pelareorep viral immunotherapy peer in GI solid tumors
- Amgen
Approved oncolytic viral therapy benchmark
- Iovance Biotherapeutics
Nonviral solid-tumor immunotherapy peer with NSCLC overlap
- Calidi Biotherapeutics
Earlier-stage oncolytic-virus delivery peer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Candel Therapeutics | $11.49 | +2.50% | $821.4M | — | — | — | — |
| Replimune Group | $13.22 | +2.75% | $1.08B | — | — | — | — |
| CG Oncology | $78.45 | +0.26% | $6.90B | — | — | 1,108.2 | — |
| Genelux | $2.61 | +1.95% | $114.8M | — | — | 14,348.9 | −98.2% |
| Oncolytics Biotech | $0.7500 | −2.13% | $76.9M | — | — | — | — |
| Amgen | $400.65 | +1.91% | $212.19B | 24.4 | 17.1 | 5.6 | +9.7% |
| Iovance Biotherapeutics | $10.27 | +0.74% | $4.55B | — | — | 14.0 | +65.7% |
| Calidi Biotherapeutics | $1.13 | +1.59% | $512.1K | — | — | — | — |
| Median | 24.4 | 17.1 | 561.1 | +9.7% |